Home  

Random  

Nearby  



Log in  



Settings  



Donate  



About Wikipedia  

Disclaimers  



Wikipedia





Dornase alfa





Article  

Talk  



Language  

Watch  

Edit  


(Redirected from Pulmozyme)
 


Dornase alfa, sold under the brand name Pulmozyme, is used for the treatment of cystic fibrosis.[3] It is a recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA.[3] Dornase alfa hydrolyzes the DNA present in sputum/mucus and reduces viscosity in the lungs, promoting improved clearance of secretions.[3] It is produced in Chinese hamster ovary cells.[3]

Dornase alfa
Clinical data
Trade namesPulmozyme
AHFS/Drugs.comMonograph
MedlinePlusa694002
License data
Pregnancy
category
  • Routes of
    administration
    Inhalation
    ATC code
    Legal status
    Legal status
    • AU: S4 (Prescription only)[1]
  • CA: ℞-only / Schedule D[2]
  • US: ℞-only[3]
  • In general: ℞ (Prescription only)
  • Identifiers
    CAS Number
    DrugBank
    ChemSpider
    • none
    UNII
    KEGG
    CompTox Dashboard (EPA)
    ECHA InfoCard100.029.685 Edit this at Wikidata
    Chemical and physical data
    FormulaC1321H1999N339O396S9
    Molar mass29254.04 g·mol−1
     ☒NcheckY (what is this?)  (verify)

    Medical uses

    edit

    Dornase alfa is indicated for the management of people with cystic fibrosis to improve pulmonary function.[3]

    Society and culture

    edit
    edit

    Dornase alfa is an orphan drug.[4]

    Research

    edit

    Dornase alfa has been shown to improve lung function in non-cystic fibrosis pre-term infants atelectasis.[5][6]

    References

    edit
    1. ^ a b Product guildlink.com.au
  • ^ "Pulmozyme Product information". Health Canada. 25 April 2012. Retrieved 9 January 2023.
  • ^ a b c d e f "Pulmozyme- dornase alfa solution". DailyMed. 21 October 2020. Retrieved 9 January 2023.
  • ^ Collier, Joe (1 September 1995). "Dornase-alfa and orphan drugs". The Lancet. 346 (8975): 633. doi:10.1016/S0140-6736(95)91460-9. PMID 7651014. S2CID 5456247.
  • ^ Erdeve O, Uras N, Atasay B, Arsan S (2007). "Efficacy and safety of nebulized recombinant human DNase as rescue treatment for persistent atelectasis in newborns: case-series". Croat Med J. 48 (2): 234–9. PMC 2080511. PMID 17436388.
  • ^ Hendriks T, de Hoog M, Lequin MH, Devos AS, Merkus PJ (2005). "DNase and atelectasis in non-cystic fibrosis pediatric patients". Crit Care. 9 (4): R351-6. doi:10.1186/cc3544. PMC 1269442. PMID 16137347.
  • Retrieved from "https://en.wikipedia.org/w/index.php?title=Dornase_alfa&oldid=1194243785"




    Last edited on 8 January 2024, at 00:23  





    Languages

     


    العربية
    Deutsch
    Español
    Italiano
    Македонски
    ି
    Polski
    Русский
    Српски / srpski
    Srpskohrvatski / српскохрватски
    Türkçe
    Українська
    Tiếng Vit
     

    Wikipedia


    This page was last edited on 8 January 2024, at 00:23 (UTC).

    Content is available under CC BY-SA 4.0 unless otherwise noted.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Terms of Use

    Desktop